These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 33970182)

  • 1. Association of a Marker of N-Acetylglucosamine With Progressive Multiple Sclerosis and Neurodegeneration.
    Brandt AU; Sy M; Bellmann-Strobl J; Newton BL; Pawling J; Zimmermann HG; Yu Z; Chien C; Dörr J; Wuerfel JT; Dennis JW; Paul F; Demetriou M
    JAMA Neurol; 2021 Jul; 78(7):842-852. PubMed ID: 33970182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-acetylglucosamine inhibits inflammation and neurodegeneration markers in multiple sclerosis: a mechanistic trial.
    Sy M; Newton BL; Pawling J; Hayama KL; Cordon A; Yu Z; Kuhle J; Dennis JW; Brandt AU; Demetriou M
    J Neuroinflammation; 2023 Sep; 20(1):209. PubMed ID: 37705084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aryl Hydrocarbon Receptor Plasma Agonist Activity Correlates With Disease Activity in Progressive MS.
    Tsaktanis T; Beyer T; Nirschl L; Linnerbauer M; Grummel V; Bussas M; Tjon E; Mühlau M; Korn T; Hemmer B; Quintana FJ; Rothhammer V
    Neurol Neuroimmunol Neuroinflamm; 2021 Mar; 8(2):. PubMed ID: 33361385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid foot-tapping but not hand-tapping ability is different between relapsing-remitting and progressive multiple sclerosis.
    Sato S; Lim J; Miehm JD; Buonaccorsi J; Rajala C; Khalighinejad F; Ionete C; Kent JA; van Emmerik REA
    Mult Scler Relat Disord; 2020 Jun; 41():102031. PubMed ID: 32172213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between Anti-CD20 Therapies and COVID-19 Severity Among Patients With Relapsing-Remitting and Progressive Multiple Sclerosis.
    Januel E; Hajage D; Labauge P; Maillart E; De Sèze J; Zephir H; Pelletier J; Guilloton L; Bensa C; Heinzlef O; Casez O; Biotti D; Bourre B; Vukusic S; Maurousset A; Berger E; Laplaud D; Lebrun-Frénay C; Dubessy AL; Branger P; Thouvenot E; Clavelou P; Sellal F; Manchon E; Moreau T; Papeix C; Tubach F; Louapre C
    JAMA Netw Open; 2023 Jun; 6(6):e2319766. PubMed ID: 37351881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of cerebrospinal fluid levels of lateral olfactory tract usher substance (LOTUS) with disease activity in multiple sclerosis.
    Takahashi K; Kurihara Y; Suzuki Y; Goshima Y; Tanaka F; Takei K
    JAMA Neurol; 2015 Feb; 72(2):176-9. PubMed ID: 25437093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-acetylglucosamine drives myelination by triggering oligodendrocyte precursor cell differentiation.
    Sy M; Brandt AU; Lee SU; Newton BL; Pawling J; Golzar A; Rahman AMA; Yu Z; Cooper G; Scheel M; Paul F; Dennis JW; Demetriou M
    J Biol Chem; 2020 Dec; 295(51):17413-17424. PubMed ID: 33453988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Arachidonic Acid-Derived Lipid Mediators With Disease Severity in Patients With Relapsing and Progressive Multiple Sclerosis.
    Broos JY; Loonstra FC; de Ruiter LRJ; Gouda M; Fung WH; Schoonheim MM; Heijink M; Strijbis EMM; Teunissen C; Killestein J; de Vries HE; Giera M; Uitdehaag BMJ; Kooij G
    Neurology; 2023 Aug; 101(5):e533-e545. PubMed ID: 37290971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of anxiety symptoms and correlates of anxiety in people with progressive and relapsing-remitting multiple sclerosis.
    Knowles LM; Tingey JL; Newman AK; von Geldern G; Alschuler KN
    Mult Scler Relat Disord; 2022 Jul; 63():103918. PubMed ID: 35700673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Corneal Confocal Microscopy to Detect Corneal Nerve Loss and Increased Dendritic Cells in Patients With Multiple Sclerosis.
    Bitirgen G; Akpinar Z; Malik RA; Ozkagnici A
    JAMA Ophthalmol; 2017 Jul; 135(7):777-782. PubMed ID: 28570722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optical coherence tomography segmentation analysis in relapsing remitting versus progressive multiple sclerosis.
    Behbehani R; Abu Al-Hassan A; Al-Salahat A; Sriraman D; Oakley JD; Alroughani R
    PLoS One; 2017; 12(2):e0172120. PubMed ID: 28192539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lower Serum Zinc Levels in Patients with Multiple Sclerosis Compared to Healthy Controls.
    Pawlitzki M; Uebelhör J; Sweeney-Reed CM; Stephanik H; Hoffmann J; Lux A; Reinhold D
    Nutrients; 2018 Jul; 10(8):. PubMed ID: 30049983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolomic profiles in relapsing-remitting and progressive multiple sclerosis compared to healthy controls: a five-year follow-up study.
    Shi T; Browne RW; Tamaño-Blanco M; Jakimovski D; Weinstock-Guttman B; Zivadinov R; Ramanathan M; Blair RH
    Metabolomics; 2023 Apr; 19(5):44. PubMed ID: 37079261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS.
    Cagol A; Benkert P; Melie-Garcia L; Schaedelin SA; Leber S; Tsagkas C; Barakovic M; Galbusera R; Lu PJ; Weigel M; Ruberte E; Radue EW; Yaldizli Ö; Oechtering J; Lorscheider J; D'Souza M; Fischer-Barnicol B; Müller S; Achtnichts L; Vehoff J; Disanto G; Findling O; Chan A; Salmen A; Pot C; Bridel C; Zecca C; Derfuss T; Lieb JM; Remonda L; Wagner F; Vargas MI; Du Pasquier RA; Lalive PH; Pravatà E; Weber J; Cattin PC; Absinta M; Gobbi C; Leppert D; Kappos L; Kuhle J; Granziera C
    Neurology; 2024 Jan; 102(1):e207768. PubMed ID: 38165377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis.
    Iwanowski P; Losy J; Kramer L; Wójcicka M; Kaufman E
    J Neurol Sci; 2017 Sep; 380():22-26. PubMed ID: 28870573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum homocysteine levels in relation to clinical progression in multiple sclerosis.
    Teunissen CE; Killestein J; Kragt JJ; Polman CH; Dijkstra CD; Blom HJ
    J Neurol Neurosurg Psychiatry; 2008 Dec; 79(12):1349-53. PubMed ID: 18676406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Score Based on NfL and Glial Markers May Differentiate Between Relapsing-Remitting and Progressive MS Course.
    Huss A; Otto M; Senel M; Ludolph AC; Abdelhak A; Tumani H
    Front Neurol; 2020; 11():608. PubMed ID: 32765393
    [No Abstract]   [Full Text] [Related]  

  • 18. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging spinal cord atrophy in progressive myelopathies: HTLV-I-associated neurological disease (HAM/TSP) and multiple sclerosis (MS).
    Azodi S; Nair G; Enose-Akahata Y; Charlip E; Vellucci A; Cortese I; Dwyer J; Billioux BJ; Thomas C; Ohayon J; Reich DS; Jacobson S
    Ann Neurol; 2017 Nov; 82(5):719-728. PubMed ID: 29024167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower serum levels of Th2-related chemokine CCL22 in women patients with multiple sclerosis: a comparison between patients and healthy women.
    Jafarzadeh A; Ebrahimi HA; Bagherzadeh S; Zarkesh F; Iranmanesh F; Najafzadeh A; Khosravimashizi A; Nemati M; Sabahi A; Hajghani H; Daneshvar H; Mohammadi MM
    Inflammation; 2014 Apr; 37(2):604-10. PubMed ID: 24254331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.